Annual report
2901.TEDINET S100X7C2
Period2025-04-01 → 2025-08-31
Filed2025-11-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 197
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.3bn | 2025-04-01 → 2025-08-31 | Cons. | Net sales |
| Revenue | ¥1.3bn | 2025-04-01 → 2025-08-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥32m | 2025-04-01 → 2025-08-31 | Cons. | Operating income |
| Operating income | ¥201m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥39m | 2025-04-01 → 2025-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥38m | 2025-04-01 → 2025-08-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥48m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥48m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥169m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥145m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥118m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥138m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥26m | 2025-04-01 → 2025-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥445m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥48m | 2025-04-01 → 2025-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥47m | 2025-04-01 → 2025-08-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥432m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥431m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥351m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥115m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥158m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥108m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥48m | 2025-04-01 → 2025-08-31 | Cons. | Profit loss |
| Net income | ¥432m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥3.8bn | at 2025-08-31 | Cons. | Assets |
| Total assets | ¥3.8bn | at 2025-08-31 | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥4.6bn | at 2025-03-31 | Cons. | Total assets (5-year summary) |
| Total assets | ¥880m | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥890m | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.0bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥554m | at 2025-08-31 | Cons. | Liabilities |
| Total liabilities | ¥1.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2025-08-31 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2025-08-31 | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2025-03-31 | Cons. | Net assets (5-year summary) |
| Net assets / equity | −¥73m | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | −¥73m | at 2024-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥133m | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥252m | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥45m | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥366m | at 2025-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥366m | at 2025-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥365m | at 2025-08-31 | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥214m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥214m | at 2024-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥211m | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥512m | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥490m | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥202m | 2025-04-01 → 2025-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥201m | 2025-04-01 → 2025-08-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥24m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥24m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥36m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥365m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥266m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥37m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥334m | 2025-04-01 → 2025-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥333m | 2025-04-01 → 2025-08-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥36m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥35m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥50m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥19m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥166m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥146m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥175m | 2025-04-01 → 2025-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥174m | 2025-04-01 → 2025-08-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥789m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥789m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥90m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥43m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥122m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥497m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥2.24 | 2025-04-01 → 2025-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.44 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.58 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.06 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.3 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-15.28 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥2.2 | 2025-04-01 → 2025-08-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.77 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥150 | at 2025-08-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥129.95 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥-5.01 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥9.14 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥17.7 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3.96 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 85.4% | at 2025-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | -8.7% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 14.7% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.0% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 4.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.6% | 2025-04-01 → 2025-08-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 31.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 51 | at 2025-08-31 | Cons. | Number of employees |
| Employees | 70 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 57 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 55 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 68 | at 2022-03-31v | Cons. | Number of employees |
| Employees | 48 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥352m | 2025-04-01 → 2025-08-31 | Standalone | Net sales |
| Revenue | ¥352m | 2025-04-01 → 2025-08-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.0bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥1.0bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥218m | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥852m | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥292m | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥287m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥20m | 2025-04-01 → 2025-08-31 | Standalone | Operating income |
| Operating income | ¥162m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | −¥28m | 2025-04-01 → 2025-08-31 | Standalone | Ordinary income |
| Ordinary income | −¥27m | 2025-04-01 → 2025-08-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥91m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥90m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥162m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥151m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥124m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥135m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥55m | 2025-04-01 → 2025-08-31 | Standalone | Income before income taxes |
| Profit before tax | ¥273m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥114m | 2025-04-01 → 2025-08-31 | Standalone | Profit loss |
| Net income | ¥114m | 2025-04-01 → 2025-08-31 | Standalone | Net income loss (5-year summary) |
| Net income | ¥272m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥271m | 2024-04-01 → 2025-03-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥342m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥121m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥172m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥146m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥3.7bn | at 2025-08-31 | Standalone | Assets |
| Total assets | ¥3.7bn | at 2025-08-31 | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥4.0bn | at 2025-03-31 | Standalone | Total assets (5-year summary) |
| Total assets | ¥629m | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥639m | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥752m | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥590m | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥202m | at 2025-08-31 | Standalone | Liabilities |
| Total liabilities | ¥1.3bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.5bn | at 2025-08-31 | Standalone | Net assets |
| Net assets / equity | ¥3.5bn | at 2025-08-31 | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.8bn | at 2025-03-31 | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥109m | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥108m | at 2024-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥301m | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥419m | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥246m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥321m | at 2025-08-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥707m | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥5.34 | 2025-04-01 → 2025-08-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.03 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.97 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.5 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.47 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-20.62 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥5.13 | 2025-04-01 → 2025-08-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥13.72 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥1.5 | 2025-04-01 → 2025-08-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥2 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥158.26 | at 2025-08-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥134.14 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6.89 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥20.88 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥29.38 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.52 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 94.4% | at 2025-08-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 16.7% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.8% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.7% | 2025-04-01 → 2025-08-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,787,000 | at 2025-08-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,557,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 15,295,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 14,295,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 14,295,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,437,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 13 | at 2025-08-31 | Standalone | Number of employees |
| Employees | 7 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 6 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 4 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 7 | at 2022-03-31v | Standalone | Number of employees |
| Employees | 7 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-08-31 | ¥240,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-08-31 | ¥240,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-08-31 | ¥11m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-08-31 | ¥57,000 |
| Reconciling Itemsreconciling | segment assets | at 2025-08-31 | ¥2.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-08-31 | −¥87m |
| Medical And Cosmeticsreportable segment | depreciation | 2025-04-01 → 2025-08-31 | ¥7m |
| Medical And Cosmeticsreportable segment | employees | at 2025-08-31 | 4 pure |
| Medical And Cosmeticsreportable segment | revenue | 2025-04-01 → 2025-08-31 | ¥193m |
| Medical And Cosmeticsreportable segment | revenue external | 2025-04-01 → 2025-08-31 | ¥193m |
| Medical And Cosmeticsreportable segment | segment assets | at 2025-08-31 | ¥301m |
| Medical And Cosmeticsreportable segment | segment profit | 2025-04-01 → 2025-08-31 | ¥44m |
| Wellnessreportable segment | capex | 2025-04-01 → 2025-08-31 | ¥11m |
| Wellnessreportable segment | depreciation | 2025-04-01 → 2025-08-31 | ¥10m |
| Wellnessreportable segment | employees | at 2025-08-31 | 44 pure |
| Wellnessreportable segment | revenue | 2025-04-01 → 2025-08-31 | ¥1.1bn |
| Wellnessreportable segment | revenue external | 2025-04-01 → 2025-08-31 | ¥1.1bn |
| Wellnessreportable segment | segment assets | at 2025-08-31 | ¥1.4bn |
| Wellnessreportable segment | segment profit | 2025-04-01 → 2025-08-31 | ¥75m |
| —segment total | capex | 2025-04-01 → 2025-08-31 | ¥11m |
| —segment total | depreciation | 2025-04-01 → 2025-08-31 | ¥18m |
| —segment total | employees | at 2025-08-31 | 48 pure |
| —segment total | revenue | 2025-04-01 → 2025-08-31 | ¥1.3bn |
| —segment total | revenue external | 2025-04-01 → 2025-08-31 | ¥1.3bn |
| —segment total | segment assets | at 2025-08-31 | ¥1.7bn |
| —segment total | segment profit | 2025-04-01 → 2025-08-31 | ¥119m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2025-08-31 | ¥11m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2025-08-31 | ¥18m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-08-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-08-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-08-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-08-31 | ¥119m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥14m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥807,000 |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥188m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥31m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥808m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥95m |
| Internet Shopping Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2m |
| Internet Shopping Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥568m |
| Internet Shopping Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥568m |
| Internet Shopping Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4m |
| Medical And Cosmeticsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥5m |
| Medical And Cosmeticsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Medical And Cosmeticsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥262m |
| Medical And Cosmeticsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥262m |
| Medical And Cosmeticsreportable segment | segment assets | at 2025-03-31 | ¥1.2bn |
| Medical And Cosmeticsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥76m |
| Wellnessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6m |
| Wellnessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥104,000 |
| Wellnessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Wellnessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Wellnessreportable segment | segment assets | at 2025-03-31 | ¥2.6bn |
| Wellnessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥214m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥10m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥5m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| —segment total | segment assets | at 2025-03-31 | ¥3.8bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥295m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥10m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥296m |
| Medical And Cosmeticsreportable segment | employees | at 2025-08-31 | 2 pure |
| Wellnessreportable segment | employees | at 2025-08-31 | 8 pure |
| —segment total | employees | at 2025-08-31 | 10 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,518
| Item | Context | Value | Unit |
|---|---|---|---|
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.429 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00471-000WellnessReportableSegmentMember | 44 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00471-000WellnessReportableSegmentMember | 23 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00471-000MedicalAndCosmeticsReportableSegmentMember | 4 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00471-000MedicalAndCosmeticsReportableSegmentMember | － | |
| Number of employees | CurrentYearInstant_ReportableSegmentsMember | 48 | |
| Average number of temporary workers | CurrentYearInstant_ReportableSegmentsMember | 23 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 3 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | － | |
| Number of employees | CurrentYearInstant | 51 | |
| Average number of temporary workers | CurrentYearInstant | 23 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 2 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 40.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5.4 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5371756 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00471-000WellnessReportableSegmentMember | 8 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00471-000WellnessReportableSegmentMember | 2 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00471-000MedicalAndCosmeticsReportableSegmentMember | 2 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00471-000MedicalAndCosmeticsReportableSegmentMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember | 10 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember | 2 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 3 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 2 | |
| Research and development expenses research and development activities | CurrentYearDuration | 265000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21787001 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 22369482 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 21787001 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 22369482 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 35 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 10 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 2564 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 2638 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 19 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 4146 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 31788 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 29745 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 77 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass rounding |
| statement vs summary · net assets | pass rounding |
| statement vs summary · net assets | pass rounding |
| statement vs summary · net assets | pass rounding |
| statement vs summary · net assets | pass rounding |
| statement vs summary · net assets | pass rounding |
| statement vs summary · net income attributable to parent | pass rounding |
| statement vs summary · net income attributable to parent | pass rounding |
| statement vs summary · operating cash flow | pass rounding |
| statement vs summary · operating cash flow | pass rounding |
| statement vs summary · revenue | pass rounding |
| statement vs summary · revenue | pass rounding |
| statement vs summary · revenue | pass rounding |
| statement vs summary · revenue | pass rounding |
| statement vs summary · total assets | pass rounding |
| statement vs summary · total assets | pass rounding |
| statement vs summary · total assets | pass rounding |
| statement vs summary · total assets | pass rounding |